Measles virus strain enders' attenuated edmonston live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Measles virus strain enders' attenuated edmonston live antigen
Accession Number
DB10315
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Description

Measles virus strain enders' attenuated edmonston live antigen is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.

Synonyms
  • Measles Virus Vaccine Live, Enders' attenuated Edmonston strain
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
M-M-R IIMeasles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.1971-04-21Not applicableUs
M-M-R IIMeasles virus strain enders' attenuated edmonston live antigen (1000 TCID50/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (12500 TCID50/0.5mL) + Rubella virus vaccine (1000 TCID50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.1979-12-31Not applicableCanada
M-M-R IIMeasles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousPhysicians Total Care, Inc.1996-08-072012-06-30Us
M-M-R IIMeasles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (12500 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousA-S Medication Solutions1971-04-21Not applicableUs
PriorixMeasles virus strain enders' attenuated edmonston live antigen (103.0 CCID50/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (103.7 CCID50/0.5mL) + Rubella virus vaccine (103.0 CCID50/0.5mL)Kit; Powder, for solutionIntramuscular; SubcutaneousGlaxosmithkline Inc1998-12-04Not applicableCanada
ProQuadMeasles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/Attenuated) (9772 [PFU]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Limited2005-09-062018-08-31Us
ProQuadMeasles virus strain enders' attenuated edmonston live antigen (3 log10 tcid50/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (4.3 log10 tcid50/0.5mL) + Rubella virus vaccine (3 log10 tcid50/0.5mL) + Varicella Zoster Vaccine (Live/Attenuated) (3.99 log10 tcid50/0.5mL)Powder, for solutionSubcutaneousMerck Ltd.2014-05-09Not applicableCanada
ProQuadMeasles virus strain enders' attenuated edmonston live antigen (1000 [TCID_50]/0.5mL) + Mumps virus strain b level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/Attenuated) (9772 [PFU]/0.5mL)Injection, powder, lyophilized, for suspensionSubcutaneousMerck Sharp & Dohme Corp.2015-07-01Not applicableUs
Categories
UNII
MFZ8I7277D
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910494

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2RecruitingOtherAcute fulminant liver failure / Heart Diseases / Renal Insufficiency,Chronic1
2Active Not RecruitingPreventionInfectious Diseases1
2CompletedPreventionChikungunya Virus Infections1
2CompletedPreventionDiseases Caused by Measles, Mumps, Rubella and Varicella Viruses / Measles-Mumps-Rubella-Varicella Vaccine / Mumps / Rubella / Rubeola / Varicella1
2CompletedPreventionMumps / Rubella / Rubeola1
2CompletedPreventionMumps / Rubella / Rubeola / Varicella1
3Active Not RecruitingPreventionVaricella1
3CompletedPreventionBacterial Infections / Virus Diseases1
3CompletedPreventionDiphtheria / Haemophilus Infections / Mumps / Pertussis / Poliomyelitis / Rubella / Rubeola / Tetanus / Varicella / Viral Hepatitis B1
3CompletedPreventionHaemophilus Influenza b Infections / Haemophilus Influenzae Type B / Meningococcal Infections / Neisseria Meningitidis / Neisseria Meningitidis-Haemophilus Influenzae Type b Vaccine1
3CompletedPreventionHaemophilus Influenzae Type B / Haemophilus Influenzae Type B Infection / Meningococcal Infections / Neisseria Meningitidis1
3CompletedPreventionHaemophilus Influenzae Type B / Neisseria Meningitidis1
3CompletedPreventionMeasles; Mumps; Rubella1
3CompletedPreventionMeningococcal Meningitis1
3CompletedPreventionMeningococcal Meningitis / Mumps / Rubella / Rubeola / Varicella1
3CompletedPreventionMumps / Rubella / Rubeola4
3CompletedPreventionMumps / Rubella / Rubeola / Varicella9
3CompletedPreventionPapillomavirus Infections1
3CompletedPreventionVaricella2
3RecruitingPreventionInfections, Pneumococcal1
3RecruitingPreventionMeningococcal Infections1
3TerminatedPreventionMumps / Rubella / Rubeola / Varicella1
3WithdrawnPreventionVaricella1
4CompletedPreventionChickenpox / Hepatitis A / Mumps / Rubella / Rubeola1
4CompletedPreventionEncephalitis, Japanese B / Mumps / Rubella / Rubeola1
4CompletedPreventionHepatitis A Virus1
4CompletedPreventionMumps / Rubella / Rubeola1
Not AvailableActive Not RecruitingNot AvailableRubeola1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for suspensionSubcutaneous
Powder, for solutionSubcutaneous
Kit; powder, for solutionIntramuscular; Subcutaneous
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:03 / Updated on July 13, 2019 00:54